All In MedTech

Device Trial Radar · NCT04683718

A First in Human Feasibility Study to Evaluate the Safety and Effectiveness of the BIOTRONIK Prospera SCS System With HomeStream Remote Management

BENEFIT-03 Clinical Study

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 20, 2021

Primary completion

Aug 21, 2025

Study completion Oct 2029

Sponsor

Lead sponsor
Biotronik, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Biotronik Australia Pty Ltd.; BIOTRONIK Neuro
First posted
Dec 24, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The BENEFIT-03 Clinical Study is a first in human, prospective, multi-center, single-arm, interventional feasibility study to be conducted in Australia. The purpose of the BENEFIT-03 study is to collect initial safety and effectiveness data on the BIOTRONIK Prosper SCS (Spinal Cord Stimulation) System with HomeStream Remote Management. Enrolled participants will complete a SCS trial period per the standard of care utilizing the BIOTRONIK Resilience percutaneous SCS trial leads and the BIOTRONIK Prospera External Pulse Generator (EPG). Following a successful trial period, participants will be implanted with a permanent BIOTRONIK Prospera Implantable Pulse Generator (IPG). Implanted participants will be followed for 24 months post-implant with in-office visits and remote management visits. For participants who consent to participate in an additional registry phase of the study, study follow-up will continue beyond 24 months with registry data collection up to 5 years post-implant.

Conditions

  • Chronic Low-back Pain
  • Chronic Leg Pain

Interventions

  • Permanent implant of a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote ManagementDevice

    The Prospera SCS System is a rechargeable, 16-electrode, MRI conditional Spinal Cord Stimulation system that delivers electrical stimulation to the dorsal column of the spinal cord for the treatment of chronic intractable pain of the trunk and/or limbs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Responder Rate to the BIOTRONIK Prospera SCS System TherapyTime frame: 6 months post-implant
  2. Primary Safety Information on the BIOTRONIK Prospera SCS SystemTime frame: 6 months post-implant

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Genesis Research Services

    Broadmeadow, New South Wales, Australia

  • Australian Medical Research

    Hurstville, New South Wales, Australia

  • Sydney Pain Research Centre

    Wahroonga, New South Wales, Australia

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.